Role of Invasive Strategy for Non-ST-Elevation Myocardial Infarction in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

[1]  Chia‐Pin Lin,et al.  Revascularization in Patients With Non-ST Elevation Myocardial Infarction and Advanced Chronic Kidney Disease. , 2022, Mayo Clinic proceedings.

[2]  I. Barbash,et al.  Early Invasive Strategy and Outcome of Non-ST-Segment Elevation Myocardial Infarction Patients With Chronic Kidney Disease. , 2022, JACC. Cardiovascular interventions.

[3]  I. Elgendy,et al.  Invasive Management for Non–ST‐Segment–Elevation Myocardial Infarction and Chronic Kidney Disease: Does One Size Fit All? , 2022, Journal of the American Heart Association.

[4]  S. Bangalore,et al.  Invasive Versus Medical Management in Patients With Chronic Kidney Disease and Non–ST‐Segment–Elevation Myocardial Infarction , 2022, Journal of the American Heart Association.

[5]  Lefeng Wang,et al.  Patients with end-stage renal disease requiring hemodialysis benefit from percutaneous coronary intervention after non-ST-segment elevation myocardial infarction , 2022, Internal and Emergency Medicine.

[6]  Theresa M. Beckie,et al.  2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2021, Circulation.

[7]  J. Cho,et al.  Outcome of early versus delayed invasive strategy in patients with non-ST-segment elevation myocardial infarction and chronic kidney disease not on dialysis. , 2021, Atherosclerosis.

[8]  Prathap Kumar,et al.  IVUS-Guided Zero-Contrast PCI in CKD Patients: Safety and Short-Term Outcome in Patients with Complex Demographics and/or Lesion Characteristics , 2021, Journal of Interventional Cardiology.

[9]  C. Herzog,et al.  Cost‐Effectiveness of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease and Acute Coronary Syndromes in the US Medicare Program , 2021, Journal of the American Heart Association.

[10]  W. Hoy,et al.  Determining the association between the type of intervention for ischaemic heart disease and mortality and morbidity in patients with chronic kidney disease , 2021, Internal medicine journal.

[11]  J. Lee,et al.  IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves , 2020, BMC Medical Research Methodology.

[12]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[13]  G. Signoriello,et al.  Left Ventricular End-Diastolic Pressure Versus Urine Flow Rate-Guided Hydration in Preventing Contrast-Associated Acute Kidney Injury. , 2020, JACC. Cardiovascular interventions.

[14]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[15]  M. Holzmann,et al.  Outcome of Percutaneous Coronary Intervention During Non–ST‐Segment–Elevation Myocardial Infarction in Elderly Patients With Chronic Kidney Disease , 2020, Journal of the American Heart Association.

[16]  Samin K. Sharma,et al.  Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. , 2020, Journal of the American College of Cardiology.

[17]  R. Mehran,et al.  Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease , 2018, Expert review of cardiovascular therapy.

[18]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[19]  B. Gersh,et al.  Non–ST‐Segment–Elevation Myocardial Infarction Among Patients With Chronic Kidney Disease: A Propensity Score–Matched Comparison of Percutaneous Coronary Intervention Versus Conservative Management , 2018, Journal of the American Heart Association.

[20]  E. Vicaut,et al.  Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials , 2017, The Lancet.

[21]  G. Stone,et al.  Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. , 2016, European heart journal.

[22]  S. de Servi,et al.  Renal dysfunction, coronary revascularization and mortality among elderly patients with non ST elevation acute coronary syndrome , 2015, European heart journal. Acute cardiovascular care.

[23]  G. Stone,et al.  Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials , 2015, Circulation. Cardiovascular interventions.

[24]  M. Gül,et al.  Effect of Contrast-Induced Nephropathy on the Long-Term Outcome of Patients with Non-ST Segment Elevation Myocardial Infarction , 2015, Cardiorenal Medicine.

[25]  Somjot S. Brar,et al.  Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial , 2014, The Lancet.

[26]  Sunil V. Rao,et al.  Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis , 2014, Open Heart.

[27]  Y. Ikari,et al.  Safety margin of minimized contrast volume during percutaneous coronary intervention in patients with chronic kidney disease , 2014, Cardiovascular Intervention and Therapeutics.

[28]  C. Torp‐Pedersen,et al.  Less use of standard guideline-based treatment of myocardial infarction in patients with chronic kidney disease: a Danish nation-wide cohort study. , 2013, European heart journal.

[29]  P. Murray,et al.  Contrast-induced acute kidney injury: how much contrast is safe? , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  K. Nikus,et al.  Coronary revascularisation in stable patients after an acute coronary syndrome: a propensity analysis of early invasive versus conservative management in a register-based cohort study , 2013, BMJ Open.

[31]  G. Stone,et al.  Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes , 2013, Annals of Internal Medicine.

[32]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[33]  Jiyan Chen,et al.  The contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy after primary percutaneous coronary intervention , 2012, International Urology and Nephrology.

[34]  J. Małyszko,et al.  Which Method of GFR Estimation Has the Best Prognostic Value in Patients Treated with Primary PCI: Cockcroft–Gault Formula, MDRD, or CKD-EPI Equation?—A 6-Year Follow-Up , 2011, Renal failure.

[35]  C. Fox,et al.  Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. , 2011, JACC. Cardiovascular interventions.

[36]  R. Kornowski,et al.  The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST‐segment elevation acute myocardial infarction , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[37]  Ju Han Kim,et al.  Management of non-ST-segment elevation acute myocardial infarction in patients with chronic kidney disease (from the Korea Acute Myocardial Infarction Registry). , 2011, The American journal of cardiology.

[38]  S. Pocock,et al.  Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. , 2010, Journal of the American College of Cardiology.

[39]  S. Yusuf,et al.  Early versus delayed invasive intervention in acute coronary syndromes. , 2009, The New England journal of medicine.

[40]  B. Mearns.  Acute coronary syndromes: Early versus late intervention in NSTEMI , 2009, Nature Reviews Cardiology.

[41]  E. Braunwald,et al.  Early angiography in patients with chronic kidney disease: a collaborative systematic review. , 2009, American Society of Nephrology. Clinical Journal.

[42]  J. Yee,et al.  Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. , 2005, Clinical nephrology.

[43]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[44]  E. Braunwald,et al.  Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.

[45]  OUP accepted manuscript , 2022, European Heart Journal.

[46]  Gordon H Guyatt,et al.  Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. , 2018, Journal of clinical epidemiology.

[47]  K. Anstrom,et al.  Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. , 2011, Journal of the American College of Cardiology.